GenomeQuest Licenses GenomeQuest™ to MIGENIX
News Apr 18, 2007
GenomeQuest, Inc. has announced that it is providing its flagship GenomeQuest™ solution to MIGENIX, Inc. GenomeQuest™ is a sequence search solution that enables biologists to evaluate gene sequences, and allows IP lawyers to evaluate freedom-to-operate, patentability, and competitive landscape features for the same sequences.
The solution combines easy-to-use sequence search and analytics with public and proprietary sequence content, including the complete indexed archive of close to 50 million patented sequences.
Dr. Dale R. Cameron, Director of Research (Anti-Infectives) and Manager, Intellectual Property, of MIGENIX, said, “The value of a cost-effective informatics platform that enables rapid and relevant search of the vast universe of sequences and their patents with regard to commercialization of new drugs cannot be understated. This is particularly true in the fast-paced R&D area of infectious disease research. We selected GenomeQuest™ for its ability to instantly locate sequence data and display it in an intuitive and easily-manipulated format.”
Ronald Ranauro, President and CEO of GenomeQuest, Inc., said, “With the exponential growth of available sequence data worldwide, having the capability to swiftly research a promising new therapeutic – or defend the IP of an existing one – is rapidly becoming a major competitive advantage in commercialization of drugs. We are very pleased to be able to offer GenomeQuest™’s services to MIGENIX in support of their drug development efforts.”
Back in 2009, researchers identified a herd of Awassi sheep suffering from "day blindness". As that term implies, these sheep were blind during the day (in bright light) but could see at night, in low-light conditions. After identifying the genetic basis of this blindness, researchers have now successfully used gene therapy to restore their daytime vision.READ MORE